BMY vs. GILD
Compare and contrast key facts about Bristol-Myers Squibb Company (BMY) and Gilead Sciences, Inc. (GILD).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BMY or GILD.
Correlation
The correlation between BMY and GILD is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
BMY vs. GILD - Performance Comparison
Loading data...
Key characteristics
BMY:
0.25
GILD:
2.06
BMY:
0.56
GILD:
2.89
BMY:
1.07
GILD:
1.36
BMY:
0.14
GILD:
1.82
BMY:
0.78
GILD:
9.96
BMY:
8.52%
GILD:
5.43%
BMY:
31.47%
GILD:
27.06%
BMY:
-70.62%
GILD:
-70.82%
BMY:
-37.21%
GILD:
-13.94%
Fundamentals
BMY:
$93.23B
GILD:
$126.28B
BMY:
$2.78
GILD:
$4.61
BMY:
16.48
GILD:
21.34
BMY:
2.26
GILD:
0.21
BMY:
1.96
GILD:
4.39
BMY:
5.16
GILD:
6.59
BMY:
$47.64B
GILD:
$28.73B
BMY:
$31.43B
GILD:
$23.07B
BMY:
$16.18B
GILD:
$9.89B
Returns By Period
In the year-to-date period, BMY achieves a -17.22% return, which is significantly lower than GILD's 9.39% return. Over the past 10 years, BMY has underperformed GILD with an annualized return of -0.74%, while GILD has yielded a comparatively higher 2.46% annualized return.
BMY
-17.22%
-8.38%
-19.97%
7.88%
-3.02%
-0.74%
GILD
9.39%
-5.05%
10.62%
55.36%
10.03%
2.46%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BMY vs. GILD — Risk-Adjusted Performance Rank
BMY
GILD
BMY vs. GILD - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and Gilead Sciences, Inc. (GILD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
BMY vs. GILD - Dividend Comparison
BMY's dividend yield for the trailing twelve months is around 5.33%, more than GILD's 3.09% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 5.33% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
GILD Gilead Sciences, Inc. | 3.09% | 3.33% | 3.70% | 3.40% | 3.91% | 4.67% | 3.88% | 3.65% | 2.90% | 2.57% | 1.27% | 0.00% |
Drawdowns
BMY vs. GILD - Drawdown Comparison
The maximum BMY drawdown since its inception was -70.62%, roughly equal to the maximum GILD drawdown of -70.82%. Use the drawdown chart below to compare losses from any high point for BMY and GILD. For additional features, visit the drawdowns tool.
Loading data...
Volatility
BMY vs. GILD - Volatility Comparison
Bristol-Myers Squibb Company (BMY) and Gilead Sciences, Inc. (GILD) have volatilities of 11.36% and 11.77%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
BMY vs. GILD - Financials Comparison
This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and Gilead Sciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BMY vs. GILD - Profitability Comparison
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.
GILD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Gilead Sciences, Inc. reported a gross profit of 5.71B and revenue of 6.67B. Therefore, the gross margin over that period was 85.6%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.
GILD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Gilead Sciences, Inc. reported an operating income of 3.15B and revenue of 6.67B, resulting in an operating margin of 47.2%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.
GILD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Gilead Sciences, Inc. reported a net income of 1.32B and revenue of 6.67B, resulting in a net margin of 19.7%.